Introduction
============

The level of non-high-density lipoproteins (non-HDL-C) was recognized as a possible modifying factor of intracranial hemorrhage in the multinational INTERSTROKE case--control study^[@bib1])^. Later, several studies found decreased total or low-density cholesterol (LDL-C) as the candidate risk factor for spontaneous intracranial hemorrhage^[@bib2]--[@bib14])^. A 2007 study with a small sample of 104 patients provided the first evidence supporting the association between cholesterol levels and hemorrhagic transformation after intravenous (IV) thrombolysis for acute ischemic stroke^[@bib5])^. Nevertheless, later studies on similar topics reported inconsistent results^[@bib5]--[@bib14])^. These studies were possibly limited by their smaller sample sizes (enrolling fewer than 500 patients)^[@bib5]--[@bib14],\ [@bib10])^, retrospective design^[@bib5]--[@bib14],\ [@bib10])^, and missing lipid profiles in a substantial portion of patients^[@bib9])^. By contrast, none of the studies determined as to how much a lower level of cholesterol contributed to the increase in symptomatic intracranial hemorrhage (SICH)^[@bib5])^ or conducted a longitudinal research on changes in the functional status in these patients. Thus, the association between decreased cholesterol levels and increased hemorrhagic transformation for acute ischemic stroke treated with IV thrombolysis is yet to be elucidated^[@bib7],\ [@bib11],\ [@bib12])^.

The Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) registry is a nationwide cohort in Taiwan and contains longitudinal follow-up data with each patient\'s clinical and laboratory characteristics for 90 days^[@bib13],\ [@bib14])^. We sought to determine whether lipid profiles (1) modified the incidence of hemorrhagic transformation at 24--36 h, and (2) altered the functional status changes in patients with acute ischemic stroke patients treated with IV thrombolysis among ethnic Chinese (i.e., Taiwanese).

Methods
=======

Design and Participants
-----------------------

This multicenter cohort study included 30 hospitals in Taiwan, and the data were prospectively collected and registered in the TTT-AIS registry system. For patients with acute ischemic stroke, IV alteplase was adopted as the thrombolytic regimen at arrival within 3 h of stroke onset. Eligible patients fulfilled the inclusion criteria of (1) treatment with IV thrombolysis adhering to the National Institute for Neurological Disorders (NINDS) standard^[@bib15])^ and (2) measurement of total cholesterol, LDL-C, HDL-C, and triglycerides (TG) in a fasting state (measured during 24--72 h following IV alteplase administration). Exclusion criteria for IV thrombolysis referred to the SITS-MOST study standard^[@bib16])^. All enrolled patients with acute ischemic stroke underwent brain computed tomography (CT) on arrival at the emergency department, and another routine repeat brain CT was conducted within 24--36 h post IV thrombolysis. Baseline demographic data including age, sex, weight, history of hypertension, diabetes mellitus, hyperlipidemia, coronary artery disease, atrial fibrillation, alcohol consumption, blood pressure on arrival, use of antiplatelet and anticoagulant medications, baseline National Institutes of Health Stroke Scale (NIHSS) score, the alteplase dose, and time from stroke onset to IV thrombolysis were retrieved by investigators. Patients with a capacity of will signed the informed consent themselves, whereas it was signed by legal surrogate in case of patients without a capacity of will. This study was approved by the institutional review board of Kaohsiung Medical University Hospital.

Outcomes Measures
-----------------

Regarding primary and secondary objectives, we evaluated the relationship between SICH and lipid profiles in two ways: (1) groups of hyperlipidemia and non-hyperlipidemia (the hyperlipidemia group was defined as total cholesterol of ≥ 200 mg/dL or LDL-C of ≥ 130 mg/dL or TG of ≥ 200 mg/dL) and (2) total cholesterol, LDL-C, HDL-C, and TG as continuous variables (mg/dL). Patients were longitudinally surveyed at 30 and 90 days for functional outcome measurement. The modified Rankin Scale (mRS) of 0--1 or 0--2 was defined as favorable functional outcomes^[@bib17])^. SICH was defined by three criteria: (1) the National Institute of Neurological Disorders (NINDS) study standard in which any intracranial hemorrhage with deterioration of NIHSS scores of ≥ 1 or death within 36 h^[@bib15])^, (2) the European Cooperative Acute Stroke Study (ECASS) II standards in which any apparently extravascular blood in the cranium with deterioration of NIHSS scores of ≥ 4 or led to death^[@bib18])^, and (3) the SITS-MOST standards in which a type 2 parenchymal hemorrhage (a local or remote parenchymal intracranial hemorrhage exceeding 30% of the infarct) with clinical deterioration of NIHSS scores of ≥ 4 or death within 36 h^[@bib16])^.

Validation Study
----------------

As a separate part of the study, we verified which lipid profile was a candidate marker for predicting SICH. In the current systems, there were seven validated risk-scoring models available for us to predict hemorrhagic transformation for acute ischemic stroke treated with IV thrombolysis. The candidate lipid profile was then incorporated into to the original risk-scoring models, which in succession became the new model. We certified a lipid profile that was in actual association with SICH by contrasting the original and new risk-scoring models (when new models had significantly better diagnostic ability than the original one). These risk-scoring systems contained the Hemorrhage After Thrombolysis (HAT) score^[@bib19])^, the Safe Implementation of Thrombolysis in Stroke (SITS-SICH) score^[@bib20])^, the Cucchiara score^[@bib21])^, the blood Sugar, Early infarct signs and hyperDense cerebral artery sign, Age, and NIHSS (SEDAN) score^[@bib22])^, the Stroke Prognostication using Age and National Institutes of Health Stroke Scaleand-100 (SPAN-100) index^[@bib23])^, the Glucose Race Age Sex Pressure Stroke Severity (GRASPS) score^[@bib24])^, and the Totaled Health Risks in Vascular Events (THRIVE) score^[@bib25])^ (**[Supplemental Table 1](#T4){ref-type="table"}**). As a separate part of the study, we investigated the subcohort of possibly statin-naive patients. Because the Taiwan National Health Insurance (TNHI) system had strict payment rule for statin, the subcohort was defined as exclusion of the TNHI rule (LDL-C of ≥ 130 mg/dL or total cholesterol of ≥ 200 mg/dL with diabetes mellitus or more than one of the following cardiovascular risk factors: HDL of \< 40 mg/dL, hypertension, male patient aged ≥ 40 years, female menopausal patient aged ≥ 55 years, or smoking). These results are shown in **[Supplemental Fig. 3](#F6){ref-type="fig"}** and **[Table 4](#T7){ref-type="table"}**.

###### The Risk-scoring Models Used in Validation Study.

  -------------------------------------------------------------------------------------------------------------------------
  Model                Variables Needed                     Cut-off values\                   Original Definition of SICH
                                                            (points obtained for each item)   
  -------------------- ------------------------------------ --------------------------------- -----------------------------
  HAT score^1^         NIHSS,\                              15--20 (1),\                      NINDS
                       \                                    \> 20 (2),\                       
                       Glucose \> 200 mg/dl or\             yes (1),\                         
                       Diabetes mellitus,\                  \                                 
                       Hypodensity on CT                    \< 1/3 of MCA territory (1),\     
                                                            ≥ 1/3 of MCA territory (2),       

  SICH score^2^        Age,\                                ≥ 72 (1),\                        SITS-MOST
                       NIHSS,\                              7--12 (1),\                       
                       \                                    ≥ 13 (2),\                        
                       Glucose,\                            ≥ 180 mg/dl (2),\                 
                       Systolic blood pressure,\            ≥ 146 mmHg (1),\                  
                       Weight,\                             ≥ 95 kg (1),\                     
                       Onset to thrombolytic time,\         ≥ 180 min (1),\                   
                       Aspirin monotherapy,\                yes (2),\                         
                       Aspirin + clopidogrel,\              yes (3),\                         
                       Hypertension,                        yes (1),                          

  Cucchiara Score^3^   Age,\                                \>60 (1),\                        NINDS
                       NIHSS,\                              \>10 (1),\                        
                       Glucose,\                            \>150 mg/dl (1),\                 
                       Platelet count,                      \< 150,000/mm^3^ (1)              

  SEDAN Score^4^       Glucose,\                            145--216 mg/dl (1),\              ECASS II
                       \                                    \>216 mg/dl (2)\                  
                       Early infarct on CT\                 yes (1)\                          
                       Dense cerebral artery sign on CT,\   \                                 
                       Age,\                                yes (1),\                         
                       NIHSS,                               \>75 (1),\                        
                                                            ≥ 10 (1),                         

  SPAN-100 index^5^    Age + NIHSS                          ≥ 100 (1)                         NINDS

  GRASP score^6^       Age,\                                ≤ 60 (8),\                        NINDS
                       \                                    61--70 (11),\                     
                       \                                    71--80 (15),\                     
                       \                                    \> 80 (17),\                      
                       NIHSS,\                              0--5 (20),\                       
                       \                                    6--10 (27),\                      
                       \                                    11--15 (34),\                     
                       \                                    16--20 (40),\                     
                       \                                    \>20 (42),\                       
                       Glucose,\                            \<100 (2)\                        
                       \                                    100--149 (6),\                    
                       \                                    ≥ 150 (8)\                        
                       Systolic blood pressure,\            \<120 (10),\                      
                       \                                    120--149 (14),\                   
                       \                                    150--179 (18),\                   
                       \                                    ≥ 180 (21),\                      
                       Ethnicity,\                          Asian (9),\                       
                       \                                    Non--Asian (0),\                  
                       Gender                               Male (4),\                        
                                                            Female (0),                       

  THRIVE score^7^      Age,\                                60--79 (1),\                      
                       \                                    ≥ 80 (2),\                        
                       NIHSS,\                              11--20 (2),\                      
                       \                                    ≥ 21 (4),\                        
                       Hypertension,\                       yes (1),\                         
                       Diabetes mellitus,\                  yes (1),\                         
                       Atrial fibrillation,                 yes (1),                          
  -------------------------------------------------------------------------------------------------------------------------

ECASS II, the European Cooperative Acute Stroke Study II; GRASPS, the Glucose Race Age Sex Pressure Stroke Severity study; HAT, the Hemorrhage After Thrombolysis study; MCA, middle cerebral artery; NINDS, the National Institute of Neurological Disorders and Stroke study; SEDAN, the blood Sugar, Early infarct signs and hyperDense cerebral artery sign, Age, and NIHSS; SICH, symptomatic intracerebral hemorrhage; SPAN-100, the Stroke Prognostication using Age and National Institutes of Health Stroke Scaleand-100 index.

![Flow diagram of subcohort identification of possibly statin-naïve patients according to the Taiwan National Health Insurance (TNHI) payment rule.](jat-26-513-g006){#F6}

Statistical Analysis
--------------------

To compare the two groups, Student *t*-test was used for continuous variables and Chi-squared test was used for categorical variables. For outcomes measures, Poisson regression model was used to determine the relative risk (RR) of SICH in the 24--36 h of interval and Binomial regression model was used to evaluate the RR for the functional outcomes at 30 and 90 days. The multivariate regressions were applied to adjust the significantly imbalanced covariates between the hyperlipidemia and non-hyperlipidemia groups. However, covariates of the antithrombotic medications were not adjusted because of missing values in most subjects. In the validation study, receiver of operating characteristics (ROC) curves were conducted to examine the diagnostic ability of each model. The Hosmer--Lemeshow test was used to examine the model of fitness (good fitness of the model was defined as *p* \> 0.05). The integrated discriminatory improvement (IDI) test was used to compare the predictive ability between the original and new models^[@bib26],\ [@bib27])^. Statistical significance was set at a *p* value of \< 0.05. All analyses were performed using SAS 9.4 software (SAS Institute, Cary, NC, USA).

Results
=======

Baseline Demographic Characteristics
------------------------------------

A total of 2373 patients with acute ischemic stroke who completed the IV thrombolysis treatment between December 1, 2004 and December 31, 2016 were registered in TTT-AIS I and II systems (**[Fig. 1](#F1){ref-type="fig"}**). Complete lipid profile data in a fasting state were measured in 1845 patients following admission (**[Table 1](#T1){ref-type="table"}**). The hyperlipidemia cohort included 747 patients, and the non-hyperlipidemia cohort included 1093 patients. The non-hyperlipidemia group was more likely to include older patients, those with a comorbidity of atrial fibrillation, those using aspirin, those with higher baseline NIHSS scores, and those using low-dose alteplase. The hyperlipidemia group consisted of more patients with higher systolic and diastolic blood pressure at arrival. There were no significant differences in the sex distribution; comorbidities of hypertension, diabetes mellitus, coronary artery disease, and alcoholism; or time from stroke onset to IV thrombolysis between the two groups.

![The flow diagram of the research. Patients were followed up at 24--36 for intracranial hemorrhage outcomes, and at 30 and 90 days for functional outcomes.](jat-26-513-g001){#F1}

###### Demographic Characteristics of Patients with and without Hyperlipidemia

  Variable                              Hyperlipidemia    No hyperlipidemia   *p* value
  ------------------------------------- ----------------- ------------------- ------------------------------------------
  Age (years)                           67.1 ± 12.3       69.8 ± 13.3         \< 0.0001[\*](#tf1){ref-type="table-fn"}
  Female sex; *n* (%)                   278 (37.2%)       388 (35.5%)         0.4517
  Lipids (mg/dL)                                                              
      Total cholesterol                 219.1 ± 37.9      156.5 ± 25.6        \< 0.0001[\*](#tf1){ref-type="table-fn"}
      LDL-C                             142.4 ± 36.8      91.1 ± 24.4         \< 0.0001[\*](#tf1){ref-type="table-fn"}
      HDL-C                             45.3 ± 35.2       46.7 ± 21.5         0.3296
      TG                                162.5 ± 110.6     93.0 ± 38.3         \< 0.0001[\*](#tf1){ref-type="table-fn"}
  Body weight (kg)                      66.4 ± 13.1       64.6 ± 12.7         0.0061[\*](#tf1){ref-type="table-fn"}
  Medical history; *n*/total *N* (%)                                          
      Hypertension                      547/747 (73.2%)   786/1093 (71.9%)    0.5356
      Diabetes mellitus                 237/747 (31.7%)   314/1093 (28.7%)    0.1679
      Coronary artery disease           88/747 (11.8%)    142/1093 (13.0%)    0.4404
      Atrial fibrillations              272/618 (44.0%)   524/933 (56.2%)     \< 0.0001[\*](#tf1){ref-type="table-fn"}
  Alcoholism; *n*/total *N* (%)         65/747 (8.7%)     79/1093 (7.2%)      0.2478
  NIHSS on arrival                      12.9 ± 7.6        13.8 ± 6.8          0.0064[\*](#tf1){ref-type="table-fn"}
  Mean of Alteplase dose (mg/kg)        0.81 ± 0.13       0.79 ± 0.14         0.0009[\*](#tf1){ref-type="table-fn"}
  Groups of Alteplase dosage                                                  0.0002[\*](#tf1){ref-type="table-fn"}
      Standard dose (0.9 mg/kg)         408/747 (54.6%)   501/1093 (45.8%)    
      Low dose (\< 0.9 mg/kg)           339/747 (45.4%)   592/1093 (54.2%)    
  Blood pressure on arrival                                                   
      Systolic blood pressure (mmHg)    164.4 ± 31.1      157.6 ± 29.6        \< 0.0001[\*](#tf1){ref-type="table-fn"}
      Diastolic blood pressure (mmHg)   93.1 ± 19.8       89.8 ± 19.4         0.0006
    Time to treatment (min)             132.7 ± 46.7      131.7 ± 46.7        0.6452
  Antithrombotic medications                                                  
      Aspirin                           79/506 (15.6%)    164/739 (22.2%)     0.0040[\*](#tf1){ref-type="table-fn"}
      Clopidogrel                       21/506 (4.2%)     33/739 (4.5%)       0.7885
      Ticlopidine                       6/506 (1.2%)      12/739 (1.6%)       0.5248
      Warfarin                          19/506 (3.8%)     31/739 (4.2%)       0.6978

HDL-C, high density lipoprotein-cholesterol; LDL-C, low density lipoprotein-cholesterol; NIHSS, National Institutes of Health Stroke Scale; TG, Triglycerides. Continuous variables are expressed as the mean ± standard deviation.

Statistically significant at *p* \< 0.05.

Primary Objective (Hyperlipidemia vs Non-Hyperlipidemia Group)
--------------------------------------------------------------

The rates of any intracranial hemorrhage (ICH) were 12.3% and 15.6% for hyperlipidemia and non-hyperlipidemia groups, respectively (**[Fig. 1](#F1){ref-type="fig"}**). Rates of SICH for hyperlipidemia and non-hyperlipidemia groups according to the NINDS, ECASS II, and SITS-MOST standards are shown in **[Table 2](#T2){ref-type="table"}**. The hyperlipidemia group had a significantly reduced incidence rate of SICH than the non-hyperlipidemia group by the NINDS standard (2.28% vs 4.85%; adjusted RR, 0.509; 95% CI, 0.277--0.933; *p* = 0.0290), the ECASS II standard (1.07% vs 2.74%; adjusted RR, 0.318; 95% CI, 0.130--0.777; *p* = 0.0119), and the SITS-MOST standard (0.27% vs 1.46%; adjusted RR, 0.216; 95% CI, 0.048--0.966; *p* = 0.0119). The continuing survey showed that the hyperlipidemia group had more patients who attained favorable functional outcomes (mRS of 0--1) than the non-hyperlipidemia group at 30 days (29.9% vs 26.2%; adjusted RR, 0.990; 95% CI, 0.860--1.141; *p* = 0.8963) and 90 days (35.3% vs 32.9%; adjusted RR, 0.962; 95% CI, 0.839--1.104; *p* = 0.5815). There was no significance difference for obtaining the favorable functional outcomes between the two groups (**[Fig. 2](#F2){ref-type="fig"}**).

###### Analysis of the Risk of Symptomatic Intracranial Hemorrhage (SICH) for the Two Cohorts at 24--36 h

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                         Hyperlipidemia    Non-hyperlipidemia   RR\                    *p* value                               Adjusted RR\                               *p* value
                                                                          (95% CI)                                                       (95% CI)^[†](#tf3){ref-type="table-fn"}^   
  -------------------------------- ----------------- -------------------- ---------------------- --------------------------------------- ------------------------------------------ ---------------------------------------
  SICH at 24--36 hrs                                                                                                                                                                

      by NINDS standard            17/747 (2.28%)    53/1093 (4.85%)      0.469 (0.274--0.804)   0.0059                                  0.509 (0.277--0.933)                       0.0290[\*](#tf2){ref-type="table-fn"}

      by ECASS II standard         8/747 (1.07%)     30/1093 (2.74%)      0.390 (0.179--0.851)   0.0180[\*](#tf2){ref-type="table-fn"}   0.318 (0.130--0.777)                       0.0119[\*](#tf2){ref-type="table-fn"}

      by SITS-MOST standard        2/747 (0.27%)     16/1093 (1.46%)      0.183 (0.042--0.795)   0.0235[\*](#tf2){ref-type="table-fn"}   0.216 (0.048--0.966)                       0.0450[\*](#tf2){ref-type="table-fn"}

  Functional outcomes at 30 days                                                                                                                                                    

      mRS of 0--1                  206/689 (29.9%)   259/987 (26.2%)      1.052 (0.990--1.119)   0.1042                                  0.990 (0.860--1.141)                       0.8936

      mRS of 0--2                  283/689 (41.1%)   375/987 (38.0%)      1.052 (0.972--1.139)   0.2073                                  0.998 (0.855--1.164)                       0.9782

  Functional outcomes at 90 days                                                                                                                                                    

      mRS of 0--1                  227/643 (35.3%)   315/959 (32.9%)      1.038 (0.966--1.116)   0.3120                                  0.962 (0.839--1.104)                       0.5815

      mRS of 0--2                  343/643 (53.3%)   530/959 (55.3%)      1.036 (0.945--1.136)   0.4508                                  0.957 (0.805--1.138)                       0.6207
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CI, confidence interval; NINDS, National Institute of Neurological Disorders and Stroke; RR relative risk; SITS-MOST, Safe Implementation of Thrombolysis in Stroke-Monitoring Study; TG, Triglycerides.

Statistically significant at *p* \< 0.05.

Poisson regression was adjusted for age, weight, atrial fibrillation, baseline NIHSS, and dose of alteplase.

![The distribution of functional outcomes at 30 and 90 days.](jat-26-513-g002){#F2}

Secondary Objective (Each Lipid Profile)
----------------------------------------

The association between SICH and each lipid profile is shown in **[Table 3](#T3){ref-type="table"}**. Increasing total cholesterol and TG levels decreased the risk of developing SICH, but they showed solitary significance in the ECASS II standard (adjusted RR, 0.908 per 10 mg/dL; 95% CI, 0.830--0.992; *p* = 0.0331) and the SITS-MOST (adjusted RR, 0.837 per 10 mg/dL; 95% CI, 0.722--0.970; *p* = 0.0331), respectively. By contrast, only LDL-C showed a significant association with all SICH standards---the NINDS standard (adjusted RR, 0.912 per 10 mg/dL; 95% CI, 0.848--0.982; *p* = 0.0145), the ECASS II standard (adjusted RR, 0.823 per 10 mg/dL; 95% CI, 0.742--0.913; *p* = 0.0002), and the SITS-MOST standard (adjusted RR, 0.846 per 10 mg/dL; 95% CI, 0.724--0.989; *p* = 0.0358). The increased HDL-C level manifested an increased risk of SICH, but it was exclusively significant for the ECASS II standard (adjusted RR, 0.837 per 10 mg/dL; 95% CI, 0.722--0.970; *p* = 0.0182).

###### Analysis of the Risk of Symptomatic Intracranial Hemorrhage (SICH) for Each Lipid Profile.

  Variable                                    RR                     *p* value                               Adjusted RR            *p* value
  ------------------------------------------- ---------------------- --------------------------------------- ---------------------- ---------------------------------------
  Total cholesterol (per 10 mg/dl increase)                                                                                         
      SICH by NINDS                           0.947 (0.895--1.002)   0.0603                                  0.956 (0.896--1.021)   0.1797
      SICH by ECASS II                        0.937 (0.867--1.013)   0.0999                                  0.908 (0.830--0.992)   0.0331[\*](#tf4){ref-type="table-fn"}
      SICH by SITS-MOST                       0.895 (0.798--1.004)   0.0588                                  0.919 (0.766--1.102)   0.3623
  LDL-C (per 10 mg/dl increase)                                                                                                     
      SICH by NINDS                           0.907 (0.852--0.967)   0.0026[\*](#tf4){ref-type="table-fn"}   0.912 (0.848--0.982)   0.0145[\*](#tf4){ref-type="table-fn"}
      SICH by ECASS II                        0.874 (0.801--0.954)   0.0026[\*](#tf4){ref-type="table-fn"}   0.823 (0.742--0.913)   0.0002[\*](#tf4){ref-type="table-fn"}
      SICH by SITS-MOST                       0.881 (0.776--0.999)   0.0493[\*](#tf4){ref-type="table-fn"}   0.846 (0.724--0.989)   0.0358[\*](#tf4){ref-type="table-fn"}
  HDL-C (per 10 mg/dl increase)                                                                                                     
      SICH by NINDS                           1.077 (1.013--1.144)   0.0171[\*](#tf4){ref-type="table-fn"}   1.064 (0.992--1.140)   0.0826
      SICH by ECASS II                        1.087 (1.005--1.175)   0.0171[\*](#tf4){ref-type="table-fn"}   1.085 (1.005--1.171)   0.0379
      SICH by SITS-MOST                       1.053 (0.921--1.207)   0.4453                                  1.045 (0.910--1.200)   0.5311
  TG (per 10 mg/dl increase)                                                                                                        
      SICH by NINDS                           0.957 (0.916--0.999)   0.0465[\*](#tf4){ref-type="table-fn"}   0.976 (0.932--1.023)   0.3076
      SICH by ECASS II                        0.981 (0.934--1.031)   0.4533                                  0.977 (0.922--1.036)   0.4389
      SICH by SITS-MOST                       0.904 (0.809--1.091)   0.0719                                  0.837 (0.722--0.970)   0.0182[\*](#tf4){ref-type="table-fn"}

HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NINDS, National Institute of Neurological Disorders and Stroke; RR, relative risk, CI, confidence interval; SITS-MOST, Safe Implementation of Thrombolysis in Stroke-Monitoring Study; TG, triglycerides.

Statistically significant at *p* \< 0.05.

Poisson regression adjusted for age, weight, atrial fibrillation, baseline NIHSS, and dose of alteplase.

Validation Study
----------------

LDL-C, which exhibited the most robust association with SICH in our study, was incorporated into all of our available and validated hemorrhagic transformation predicting models in two ways: continuous level and discrete points. To obtain a higher sensitivity, we determined a cut-off of LDL-C of 100--mg/dL as a point of 1, and LDL-C \< 100 mg/dL as a point of 2. For the new models with LDL-C as continuous levels, all the models showed significantly exceeding improvement in diagnostic ability. The ROC contrast results were all significant as well (**[Supplemental Table 2](#T5){ref-type="table"}**). In addition, the diagnostic ability of all models improved on adding the LDL-C discrete points, and most of them were effective in model stability and fitness (**[Supplemental Table 3](#T6){ref-type="table"}**). By applying the new models, our patients had better predictability of SICH in the NINDS standard (**[Fig. 3](#F3){ref-type="fig"}**), the ECASS II standard (**[Supplemental Fig. 1](#F4){ref-type="fig"}**), and STIS-MOST standard (**[Supplemental Fig. 2](#F5){ref-type="fig"}**).

###### The Original and New Models with LDL variable (continuous) for Predicting Symptomatic Intracranial Hemorrhage.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                   Model Odds Ratio\       *P* value     LDL Odds Ratio\        *P* value   ROC *c*\     IDI\    *P* value   Hosmer-Lemeshow\      *P* value
                                                   (per score change)                    (per mg/dL change)                 statistics   (%)                 statistics (*χ*^2^)   
  ------------------------------------------------ ----------------------- ------------- ---------------------- ----------- ------------ ------- ----------- --------------------- -----------
  Original Models by the NINDS Standard                                                                                                                                            

      HAT                                          1.739 (1.427--2.120)    \< 0.0001\*   --                     --          0.6575       --      --          0.153 (4 groups)      0.9265

      SITS-SICH                                    1.312 (1.179--1.461)    \< 0.0001\*   --                     --          0.6310       --      --          4.259 (7 groups)      0.5128

      Cucchiara                                    1.750 (1.375--2.227)    \< 0.0001\*   --                     --          0.6358       --      --          2.596 (4 groups)      0.2731

      SEDAN                                        1.599 (1.334--1.917)    \< 0.0001\*   --                     --          0.6521       --      --          3.338 (5 groups)      0.3424

      SPAN-100                                     2.147 (1.308--3.525)    0.0025\*      --                     --          0.5567       --      --          --                    --

      GRASPS                                       1.074 (1.047--1.102)    \< 0.0001\*   --                     --          0.6698       --      --          6.995 (9 groups)      0.4294

      THRIVE                                       1.299 (1.162--1.453)    \< 0.0001\*   --                     --          0.6392       --      --          2.338 (7 groups)      0.8007

  New model with LDL-C by the NINDS Standard                                                                                                                                       

      HAT                                          1.740 (1.404--2.157)    \< 0.0001\*   0.990 (0.984--0.997)   0.0023\*    0.6850       0.707   0.0034\*    2.723 (10 groups)     0.9505

      SITS-SICH                                    1.319 (1.172--1.484)    \< 0.0001\*   0.990 (0.984--0.997)   0.0023\*    0.6701       0.691   0.0100\*    11.856 (10 groups)    0.1578

      Cucchiara                                    1.956 (1.504--2.545)    \< 0.0001\*   0.990 (0.984--0.997)   0.0023\*    0.6842       0.904   0.0003\*    3.308 (10 groups)     0.9136

      SEDAN                                        1.664 (1.364--2.031)    \< 0.0001\*   0.990 (0.984--0.997)   0.0023\*    0.7040       0.817   0.0018\*    20.615 (10 groups)    0.0082\*

      SPAN-100                                     2.498 (1.472--4.241)    0.0007\*      0.990 (0.984--0.997)   0.0023\*    0.6369       0.775   0.0006\*    13.589 (10 groups)    0.0931

      GRASPS                                       1.074 (1.043--1.105)    \< 0.0001\*   0.990 (0.984--0.996)   0.0020\*    0.6873       0.626   0.0087\*    5.629 (10 groups)     0.6887

      THRIVE                                       1.323 (1.170--1.496)    \< 0.0001\*   0.990 (0.984--0.997)   0.0023\*    0.6713       0.773   0.0010\*    12.108 (10 groups)    0.1465

  Original Models by the ECASS II Standard                                                                                                                                         

      HAT                                          1.702 (1.321--2.194)    \< 0.0001\*   --                     --          0.6532       --      --          0.9222 (4 groups)     0.6306

      SITS-SICH                                    1.377 (1.215--1.586)    \< 0.0001\*   --                     --          0.6638       --      --          5.6208 (7 groups)     0.3449

      Cucchiara                                    1.807 (1.322--2.469)    0.0002\*      --                     --          0.6434       --      --          9.6871 (4 groups)     0.0079\*

      SEDAN                                        1.791 (1.420--2.258)    \< 0.0001\*   --                     --          0.6975       --      --          5.6336 (5 groups)     0.1309

      SPAN-100                                     1.905 (0.990--3.665)    0.0536        --                     --          0.5466       --      --          --                    --

      GRASPS                                       1.084 (1.048--1.122)    \< 0.0001\*   --                     --          0.6890       --      --          7.0191 (9 groups)     0.4269

      THRIVE                                       1.279 (1.107--1.476)    0.0008\*      --                     --          0.6361       --      --          3.9933 (7 groups)     0.5504

  New model with LDL-C by the ECASS II Standard                                                                                                                                    

      HAT                                          1.735 (1.311--2.297)    \< 0.0001\*   0.988 (0.980--0.996)   0.0042\*    0.7082       0.475   0.0577      9.989 (10 groups)     0.2658

      SITS-SICH                                    1.414 (1.219--1.641)    \< 0.0001\*   0.988 (0.980--0.996)   0.0042\*    0.7067       0.732   0.0217\*    12.162 (10 groups)    0.1441

      Cucchiara                                    2.012 (1.425--2.843)    \< 0.0001\*   0.988 (0.980--0.996)   0.0042\*    0.6997       0.656   0.0184\*    12.171 (10 groups)    0.1437

      SEDAN                                        1.978 (1.524--2.567)    \< 0.0001\*   0.988 (0.980--0.996)   0.0042\*    0.7670       0.651   0.0054\*    14.015 (10 groups)    0.0814

      SPAN-100                                     2.657 (1.346--5.246)    0.0049\*      0.988 (0.980--0.996)   0.0042\*    0.6524       0.659   0.0051\*    14.253 (10 groups)    0.0754

      GRASPS                                       1.088 (1.047--1.130)    \< 0.0001\*   0.988 (0.980--0.996)   0.0038\*    0.7231       0.510   0.0684      7.303 (10 groups)     0.5043

      THRIVE                                       1.324 (1.127--1.556)    0.0006\*      0.988 (0.980--0.996)   0.0042\*    0.6981       0.529   0.0330\*    14.008 (10 groups)    0.0815

  Original Models by the SITS-MOST Standard                                                                                                                                        

      HAT                                          2.359 (1.634--3.495)    \< 0.0001\*   --                     --          0.7526       --      --          0.3629 (4 groups)     0.8341

      SITS-SICH                                    1.416 (1.179--1.701)    0.0002\*      --                     --          0.7090       --      --          4.7692 (7 groups)     0.4447

      Cucchiara                                    2.169 (1.378--3.414)    0.0008\*      --                     --          0.6894       --      --          24.080 (4 groups)     0.0001\*

      SEDAN                                        1.936 (1.398--2.680)    \< 0.0001\*   --                     --          0.7185       --      --          2.869 (5 groups)      0.4122

      SPAN-100                                     2.394 (0.998--5.742)    0.0504        --                     --          0.5679       --      --          --                    --

      GRASPS                                       1.093 (1.041--1.147)    0.0003\*      --                     --          0.7041       --      --          6.046 (9 groups)      0.5343

      THRIVE                                       1.387 (1.128--1.705)    0.0019\*      --                     --          0.6792       --      --          10.576 (7 groups)     0.0605

  New model with LDL-C by the SITS-MOST Standard                                                                                                                                   

      HAT                                          2.662 (1.733--4.091)    \< 0.0001\*   0.987 (0.975--0.999)   0.0373\*    0.8098       0.613   0.0541      3.894 (10 groups)     0.8665

      SITS-SICH                                    1.489 (1.207--1.836)    0.0002\*      0.987 (0.975--0.999)   0.0373\*    0.7680       0.419   0.0384\*    8.473 (10 groups)     0.3887

      Cucchiara                                    3.156 (1.831--5.441)    \< 0.0001\*   0.987 (0.975--0.999)   0.0373\*    0.7851       0.982   0.0391\*    9.803 (10 groups)     0.2792

      SEDAN                                        2.444 (1.655--3.610)    \< 0.0001\*   0.987 (0.975--0.999)   0.0373\*    0.8179       0.347   0.0207\*    12.351 (10 groups)    0.1362

      SPAN-100                                     3.987 (1.554--10.245)   0.0040\*      0.987 (0.975--0.999)   0.0373\*    0.6713       0.553   0.0277\*    11.385 (10 groups)    0.1808

      GRASPS                                       1.107 (1.042--1.175)    \< 0.0001\*   0.987 (0.974--0.999)   0.0356\*    0.7512       0.476   0.0329\*    2.384 (10 groups)     0.9669

      THRIVE                                       1.497 (1.170--1.916)    0.0013\*      0.987 (0.975--0.999)   0.0373\*    0.7389       0.542   0.0839      14.946 (10 groups)    0.0602
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ECASS II, the European Cooperative Acute Stroke Study II; GRASPS, Glucose Race Age Sex Pressure Stroke Severity; HAT, Hemorrhage After Thrombolysis; LDL-C, lower density lipoprotein-cholesterol; NINDS, National Institute of Neurological Disorders and Stroke; ROC, receiver operating characteristic; SICH, symptomatic intracerebral hemorrhage; SPAN-100, Stroke Prognostication using Age and National Institutes of Health Stroke Scaleand-100.

###### Original and New Risk Scoring Systems Models with (discrete) LDL-C Scores for Predicting Symptomatic Intracranial Hemorrhage

  --------------------------------------------------------------------------------------------------------------------------------------------
                                                            Model Odds Ratio\      *P* value     ROC *c*\     Hosmer --Lemeshow\   *P* value
                                                            (per score change)                   statistics   statistics           
  --------------------------------------------------------- ---------------------- ------------- ------------ -------------------- -----------
  Original models                                                                                                                  

      HAT                                                   1.739 (1.427--2.120)   \< 0.0001\*   0.6575       0.1527 (4 groups)    0.9265

      SITS-SICH                                             1.312 (1.179--1.461)   \< 0.0001\*   0.6310       4.2587 (7 groups)    0.5128

      Cucchiara                                             1.750 (1.375--2.227)   \< 0.0001\*   0.6358       2.5957 (4 groups)    0.2731

      SEDAN                                                 1.599 (1.334--1.917)   \< 0.0001\*   0.6521       3.3382 (5 groups)    0.3424

      SPAN-100                                              2.147 (1.308--3.525)   0.0025\*      0.5567       --                   --

      GRASPS                                                1.074 (1.047--1.102)   \< 0.0001\*   0.6698       6.9952 (9 groups)    0.4294

      THRIVE                                                1.299 (1.162--1.453)   \< 0.0001\*   0.6392       2.3377 (7 groups)    0.8007

  New models with LDL-C risk scores by NINDS criteria                                                                              

      HAT                                                   1.589 (1.352--1.869)   \< 0.0001\*   0.6687       4.4057 (6 groups)    0.3539

      SITS-SICH                                             1.327 (1.200--1.467)   \< 0.0001\*   0.6567       0.6450 (7 groups)    0.9859

      Cucchiara                                             1.530 (1.283--1.826)   \< 0.0001\*   0.6434       0.1585 (5 groups)    0.9840

      SEDAN                                                 1.560 (1.333--1.825)   \< 0.0001\*   0.6756       4.5016 (5 groups)    0.2117

      SPAN-100                                              1.543 (1.202--1.983)   0.0007\*      0.5980       2.2371 (4 groups)    0.3268

      GRASPS                                                1.077 (1.049--1.104)   \< 0.0001\*   0.6756       4.0071 (10 groups)   0.8565

      THRIVE                                                1.297 (1.172--1.435)   \< 0.0001\*   0.6499       8.4462 (7 groups)    0.1333

  New models with LDL-C risk scores by ECASS II criteria                                                                           

      HAT                                                   1.601 (1.300--1.973)   \< 0.0001\*   0.6790       4.9357 (6 groups)    0.2940

      SITS-SICH                                             1.406 (1.239--1.595)   \< 0.0001\*   0.6888       7.4850 (7 groups)    0.1870

      Cucchiara                                             1.800 (1.357--2.388)   \< 0.0001\*   0.6599       3.1769 (5 groups)    0.2042

      SEDAN                                                 1.735 (1.415--2.126)   \< 0.0001\*   0.7169       1.4369 (5 groups)    0.6969

      SPAN-100                                              1.581 (1.411--2.190)   0.0059\*      0.6015       1.2868 (4 groups)    0.5255

      GRASPS                                                1.087 (1.051--1.124)   \< 0.0001\*   0.6963       5.5266 (10 groups)   0.7001

      THRIVE                                                1.290 (1.132--1.470)   \< 0.0001\*   0.6571       9.7999 (7 groups)    0.0811

  New models with LDL-C risk scores by SITS-MOST criteria                                                                          

      HAT                                                   2.505 (1.748--3.590)   \< 0.0001\*   0.7776       2.8237 (5 groups)    0.4196

      SITS-SICH                                             1.464 (1.222--1.754)   \< 0.0001\*   0.7301       5.3503 (4 groups)    0.3746

      Cucchiara                                             2.277 (1.498--3.461)   \< 0.0001\*   0.7234       13.1442 (4 groups)   0.0014\*

      SEDAN                                                 1.972 (1.476--2.635)   \< 0.0001\*   0.7596       1.6954 (5 groups)    0.6380

      SPAN-100                                              2.039 (1.243--2.342)   0.0047\*      0.6492       1.6072 (4 groups)    0.4477

      GRASPS                                                1.097 (1.046--1.152)   0.0002\*      0.7140       3.8193 (10 groups)   0.8730

      THRIVE                                                1.421 (1.175--1.719)   \< 0.0001\*   0.7035       7.3688 (7 groups)    0.1946
  --------------------------------------------------------------------------------------------------------------------------------------------

ECASS II, the European Cooperative Acute Stroke Study II; GRASPS, Glucose Race Age Sex Pressure Stroke Severity; HAT, Hemorrhage After Thrombolysis; LDL-C, Low density lipoprotein-cholesterol; NINDS, National Institute of Neurological Disorders and Stroke; ROC, receiver operating characteristic; SICH, symptomatic intracerebral hemorrhage; SPAN-100, Stroke Prognostication using Age and National Institutes of Health Stroke Scaleand-100.
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Discussion
==========

In this investigation, hyperlipidemia had a robust protective effect on the development of SICH among patients with acute ischemic stroke treated with IV thrombolysis, but not for the favorable functional outcomes at 30 and 90 days. The study confirmed that the association between the lipid profile and SICH was mostly attributable to LDL-C, and a level of LDL-C \< 130 mg/dL had the greatest significant association with increased SICH.

In our cohorts, the ICH and SICH rates varied according to the NINDS, ECASS II, and SITS-MOST. Because the SITS-MOST standard had the most conservative definition, the SICH rates were markedly reduced in the hyperlipidemia and non-hyperlipidemia groups (0.27% and 1.46%, respectively). This was comparable to previous literature^[@bib13],\ [@bib14])^ and also reflected real-world data among Asian population. Moreover, our cohorts had high follow-up rates in both groups (92.2% and 90.4%, respectively, at 30 days; 86.1% and 87.7%, respectively, at 90 days). These high follow-up rates should strengthen our research by avoiding the selection bias.

In the validation section, we confirmed LDL-C had high diagnostic ability in predicting hemorrhagic transformation. Each of the modified risk scoring model implementing LDL-C variable had higher ROC statistics (the area under curve) in predicting SICH and maintained stable goodness of fit. The modified models in a way of LDL-C discrete points also exempted from the doubt of increasing diagnostic ability by adding another variable. For an example, the discrete points models of HAT score synthesized all scoring variables (including the LDL-C) into single value in a range from 0, 1, 2, ≥ 3 which called as total score. Only the total score was used as the independent variable in these modified models. These modified models verified our judgment and raised the practical ability (**[Fig. 3](#F3){ref-type="fig"}**, **[Supplemental Figs. 1](#F4){ref-type="fig"}** and **[2](#F5){ref-type="fig"}**).

From earlier studies such as the INTERSTROKE study, we recognized that non-HDL-C was possibly connected with spontaneous ICH occurrence. Our study showed that increased TG may be protective, but it was only significant in the SITS-MOST standard. Referred to the previous literature of TG, which showed inconsistent results^[@bib28]--[@bib14])^, we supposed TG was not a reliable marker for hemorrhagic transformation. For increased HDL-C level, our results showed a paradoxically raised risk of hemorrhagic transformation despite only significant in the ECASS II standard. The relevant studies showed a similar trend for HDL-C^[@bib29],\ [@bib30],\ [@bib33],\ [@bib34])^, but most of their results were not significant like our study results. Regarding LDL-C, a recent study proposed that admission ICH volume in cube root was inversely proportional to admission LDL-C levels^[@bib35])^. We considered that low LDL-C may modify the SICH through increasing ICH volume expansion, but all lipid profiles did not effectively alter the long-term outcomes. This warrants further studies.

The distinctive strengths of our study are (1) a longitudinal cohort study design with a large sample size of patients treated with a thrombolytic agent in comparison to previous studies, (2) determination of how much a lower level of LDL-C contributed to increase hemorrhagic transformation of SICH, (3) a solid definition of SICH by the NINDS, ECASS II, and SITS-MOST standards, (4) a validation study to substantiate our findings, and (5) a proper statistical estimation. We adopted the Poisson regression instead of logistic regression model because the former produces a more unbiased estimate when adjusting for confounders^[@bib36],\ [@bib37])^ and our prime data fulfilled the assumption of the Poisson regression (the count of SICH events was rare and the sample size of enrolled patients was large).

This study has some limitations. First, the TTT-AIS registry^[@bib13],\ [@bib14])^ has no exact information on whether patients treated with a thrombolytic agent took statins. However, we may identify the patients who were possibly statin-naive because the TNHI system had strict payment rule for statin and covered all residents in Taiwan. Although we cannot thoroughly discuss the interaction with statins, we found that these possibly statin-naive patients still had an increased association between low LDL-C and SICH (**[Supplemental Fig. 3](#F6){ref-type="fig"}** and **[Supplemental Table 4](#T7){ref-type="table"}**). Second, the TTT-AIS registry^[@bib13],\ [@bib14])^ had not enrolled patients treated with intra-arterial thrombectomy. The TTT-AIS was launched in 2004 at that time the intra-arterial thrombectomy technique had not been introduced in Taiwan. Third, the TTT-AIS registry had no nutrient-related information. Nonetheless, our results should stay free from the doubt of malnutrition influence. Compared to the neighboring Asian countries, the National Health and Nutrition Examination Survey (NHANES)^[@bib38])^ in Taiwan reported that our population had the highest average number of body mass index and metabolic syndrome, and the prevalence of obesity was also proportional to increasing age. These also highlight the importance of this research investigating the association between thrombolytic outcomes and lipid profiles.

###### Subcohort Analysis of Association between Lipid Profile and Symptomatic Intracranial Hemorrhage for Possibly Statin-naïve Patients

  Variable                                    RR                     *p* value                               Adjusted RR            *p* value
  ------------------------------------------- ---------------------- --------------------------------------- ---------------------- ---------------------------------------
  Total cholesterol (per 10 mg/dl increase)                                                                                         
      SICH by NINDS                           0.948 (0.869--1.035)   0.2341                                  0.971 (0.879--1.072)   0.5599
      SICH by ECASS II                        1.009 (0.900--1.132)   0.8760                                  0.997 (0.879--1.130)   0.9582
      SICH by SITS-MOST                       0.985 (0.837--1.159)   0.8536                                  0.934 (0.764--1.140)   0.4998
  LDL-C (per 10 mg/dl increase)                                                                                                     
      SICH by NINDS                           0.866 (0.789--0.950)   0.0023[\*](#tf6){ref-type="table-fn"}   0.873 (0.783--0.973)   0.0143[\*](#tf6){ref-type="table-fn"}
      SICH by ECASS II                        0.894 (0.791--1.012)   0.0760                                  0.856 (0.746--0.983)   0.0270[\*](#tf6){ref-type="table-fn"}
      SICH by SITS-MOST                       0.991 (0.821--1.198)   0.9289                                  0.932 (0.743--1.170)   0.5447
  HDL-C (per 10 mg/dl increase)                                                                                                     
      SICH by NINDS                           1.076 (0.998--1.159)   0.0550                                  1.064 (0.984--1.190)   0.1036
      SICH by ECASS II                        1.080 (0.982--1.189)   0.1145                                  1.115 (0.995--1.249)   0.0608
      SICH by SITS-MOST                       1.031 (0.878--1.212)   0.7093                                  1.051 (0.855--1.292)   0.6363
  TG (per 10 mg/dl increase)                                                                                                        
      SICH by NINDS                           0.982 (0.938--1.027)   0.4262                                  1.000 (0.959--1.044)   0.9901
      SICH by ECASS II                        1.001 (0.967--1.053)   0.6845                                  1.006 (0.960--1.055)   0.7929
      SICH by SITS-MOST                       0.944 (0.850--1.048)   0.2788                                  0.882 (0.761--1.022)   0.0935

HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; N, total number of subcohort patients; NINDS, National Institute of Neurological Disorders and Stroke; RR, relative risk, CI, confidence interval; SITS-MOST, Safe Implementation of Thrombolysis in Stroke-Monitoring Study; TG, triglycerides.

Statistically significant at *p* \< 0.05.

Poisson regression adjusted for age, weight, atrial fibrillation, baseline NIHSS, and dose of alteplase.

In conclusion, this study supports an association between reduced lipid profiles and increased SICH among patients with acute ischemic stroke treated with IV thrombolysis. LDL-C level of \< 130 mg/dL is a candidate marker indicating increased SICH after IV thrombolysis.
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